ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.

被引：5
|
作者：
Mirza, Mansoor Raza
Mortensen, Christiane Ehlers
Avall-Lundqvist, Elisabeth
Bjorge, Line
Berek, Jonathan S.
Herrstedt, Jorn
Holm, Anne Juul
Kirkegaard, Tinne
Maenpaa, Johanna
机构：
[1] Copenhagen Univ Hosp, NSGO, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Linkoping Univ, Dept Oncol, Linkoping, Sweden
[4] Linkoping Univ, Dept Clin Expt Med, Linkoping, Sweden
[5] Karolinska Inst, Linkoping, Sweden
[6] Dept Obstet & Gynecol, Bergen, Norway
[7] Stanford Womens Canc Ctr, Stanford, CA USA
[8] Odense Univ Hosp, DK-5000 Odense, Denmark
[9] NSGO, Copenhagen, Denmark
[10] Tampere Univ Hosp, Tampere, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps5607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5607
引用
收藏
页数：1
相关论文
共 45 条
  • [31] ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC)
    Perren, T.
    Swart, A. M.
    Pfisterer, J.
    Ledermann, J.
    Lortholary, A.
    Kristensen, G.
    Carey, M.
    Beale, P.
    Cervantes, A.
    Oza, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 2 - 3
  • [32] OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).
    Aghajanian, C.
    Finkler, N. J.
    Rutherford, T.
    Smith, D. A.
    Yi, J.
    Parmar, H.
    Nycum, L. R.
    Sovak, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Aghajanian, C.
    Finkler, N. J.
    Rutherford, T.
    Smith, D. A.
    Yi, J.
    Parmar, H.
    Nycum, L. R.
    Sovak, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [34] ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Herzog, Thomas J.
    Moore, Kathleen N.
    Konstantinopoulos, Panagiotis A.
    Gilbert, Lucy
    Hays, John L.
    Monk, Bradley J.
    O'Malley, David M.
    Sehouli, Jalid
    Barlin, Joyce N.
    Graham, Julie R.
    Md, Monali Desai
    Wang, Yan
    Du, Yangchun
    Dalal, Rita P.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
    Aghajanian, C.
    Blank, S. V.
    Goff, B.
    Judson, P. L.
    Makhija, S.
    Sharma, S. K.
    Nycum, L. R.
    Yi, J.
    Husain, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 5 - 5
  • [36] Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)
    Kurtz, J. E.
    Pujade-Lauraine, E.
    Oaknin, A.
    Belin, L.
    Grimm, C.
    Kocian, R.
    Denys, H.
    Rosengarten, O. S.
    Follana, P.
    Sehouli, J.
    Martinez-Garcia, J.
    Alexandre, J.
    Hardy-Bessard, A-C.
    Frenel, J-S.
    Sabatier, R.
    Gladieff, L.
    Rouge, T. De La Motte
    Lamichhane, N. Bonichon
    Kalbacher, E.
    Heitz, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S546 - S546
  • [37] An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
    Tadahiro Shoji
    Shinichi Komiyama
    Junzo Kigawa
    Hiroshi Tanabe
    Kazuyoshi Kato
    Hiroaki Itamochi
    Hiroyuki Fujiwara
    Shoji Kamiura
    Tetsutaro Hamano
    Toru Sugiyama
    BMC Cancer, 18
  • [38] An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
    Shoji, Tadahiro
    Komiyama, Shinichi
    Kigawa, Junzo
    Tanabe, Hiroshi
    Kato, Kazuyoshi
    Itamochi, Hiroaki
    Fujiwara, Hiroyuki
    Kamiura, Shoji
    Hamano, Tetsutaro
    Sugiyama, Toru
    BMC CANCER, 2018, 18
  • [39] ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
    Hardy-Bessard, Anne-Claire
    Moore, Kathleen N.
    Mirza, Mansoor Raza
    Asselain, Bernard
    Redondo, Andres
    Pfisterer, Jacobus
    Pignata, Sandro
    Provencher, Diane M.
    Cibula, David
    Reyners, Anna K. L.
    Bodnar, Lubomir
    Glasspool, Rosalind Margaret
    Papadimitriou, Christos A.
    Eitan, Rami
    Han, Sileny
    Duska, Linda R.
    Rimel, Bj
    Hazard, Sebastien
    Chen, Jian
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Optimal Treatment Duration of Bevacizumab Combined With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer: A Multicenter Open-Label Randomized 2-Arm Phase 3 ENGOT/GCIG Trial of the AGO Study Group, GINECO, and NSGO (AGO- OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 16 - 17
12345